Eikon Therapeutics (EIKN)

Executive Summary

Eikon Therapeutics is a publicly traded biotechnology company that integrates advanced microscopy and machine learning to track individual protein movements in living cells, enabling the discovery of novel therapeutics. The company's platform aims to identify new biological targets and drug candidates across oncology and immunology. Eikon's pipeline includes five disclosed candidates, with the most advanced being: EIK1004-001 (IMP1707-001) in a Phase 1/2 trial for advanced solid tumors (NCT06907043, recruiting since April 2025), IMP1734 in a Phase 1/2 trial for advanced solid tumors (NCT06253130, recruiting since December 2023), and EIK1001 in combination with pembrolizumab and chemotherapy for NSCLC in a Phase 2 trial (NCT06246110, recruiting since February 2024). The company also completed Phase 1/2 trials for BDB001. With a market capitalization of ~$497 million, Eikon is well-positioned to generate early clinical data in the coming years. However, as a relatively young public company (IPO likely in 2021-2022) with only early-stage clinical assets, significant regulatory and execution risks remain.

Upcoming Catalysts (preview)

• H2 2026Interim data from Phase 1/2 trial of EIK1004-001 (IMP1707-001) in advanced solid tumors40% success
• H2 2026Interim data from Phase 1/2 trial of IMP1734 in advanced solid tumors40% success
• H1 2027Enrollment completion for Phase 2 trial of EIK1001 combo in NSCLC60% success